A Study to Assess the Safety, Tolerability, and Pharmacodynamics of MK-8931/SCH 900931 in Patients With Alzheimer's Disease [Phase 1b; Protocol No. 010-00 (Also Known as P07820)].
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Verubecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- 02 Nov 2016 According to Merck & Co media release, reults were published online in Science Translational Medicine journal.
- 02 Nov 2016 Results published in the Merck & Co Media Release.
- 14 Jul 2013 Results presented at the Alzheimer's Association International Conference (AAIC), according to a media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History